Filing Flows › ADC Therapeutics SA (ADCT) › Q3 2026 › vs Q3 2025
ADC Therapeutics SA (ADCT) Q3 2026 vs Q3 2025 (year over year)
ADC Therapeutics SA's revenue rose $5.3M (+32%) from $16.4M in Q3 2025 to $21.7M in Q3 2026. The biggest changes: Product revenues, net +$5.3M (+33%); License revenues and royalties +$33K (+5%).
ADC Therapeutics SA, Q3 2026: revenue $21.7M (+32% year over year), operating margin -66.1%, net loss $25.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product revenues, net | $21.0M | $15.8M | $5.3M | +33% |
| License revenues and royalties | $710K | $677K | $33K | +5% |
| Revenue | $21.7M | $16.4M | $5.3M | +32% |
| Net loss | $25.3M | $41.0M | −$15.7M | -38% |
| Costs & expenses | $47.0M | $57.4M | −$10.4M | -18% |
| Operating costs | $36.1M | $47.4M | −$11.3M | -24% |
| Interest & other, net | $11.0M | $10.0M | $957K | +10% |
| Research & development | $14.7M | $26.8M | −$12.1M | -45% |
| Sales & marketing | $8.7M | $10.7M | −$2.0M | -19% |
| General & admin | $10.7M | $8.3M | $2.4M | +29% |
| Other operating costs | $1.9M | $1.6M | $339K | +21% |
Questions
How much did ADC Therapeutics SA's revenue grow year over year in Q3 2026?
ADC Therapeutics SA's revenue rose $5.3M (+32%) from $16.4M in Q3 2025 to $21.7M in Q3 2026.
What drove ADC Therapeutics SA's revenue change in Q3 2026?
Product revenues, net +$5.3M (+33%); License revenues and royalties +$33K (+5%).